Skip to main content
  • English
  • Español
Oryzon
  • Company
    • Overview
    • Strategy
    • Team
  • Epigenetics
    • Epigenetics
    • LSD1
  • Programs
    • Pipeline
    • Iadademstat
    • Vafidemstat
    • Collaborations
    • Publications
  • Patients
    • Clinical Trials
  • Investors
    • Share Information
      • Share Performance
      • Shares and Capital Structure
      • Dividends
      • Share Issues
      • Takeover Bids
      • Shareholdings
    • Financial Information
      • Financial Results and Accounts
      • Public Periodic Information
      • Average supplier payment period
    • Inside information
    • Other relevant information
    • Analyst Coverage
    • Corporate Governance
      • General Shareholders Meeting
      • Board of Directors
      • Board Committees
      • Shareholder Agreements
      • Annual Corporate Governance Reports
      • Annual Director Remuneration Reports
    • Corporate Social Responsibility
  • News & Events
    • Press releases
    • Events
  • Contact
    • Contact
    • Email Alerts
    • Join us

Pioneering
personalized medicine
in epigenetics

Oryzon now

5 May 2022

ORYZON reports results and corporate update for quarter ended March 31, 2022

Read more
3 May 2022

ORYZON starts preclinical collaboration on Kabuki syndrome with Kennedy Krieger Institute and Johns Hopkins University

Read more
29 April 2022

ORYZON to give updates on corporate progress in May

Read more

ORYZON is a public clinical stage biopharmaceutical company developing innovative epigenetic personalized medicines for patients with cancer and CNS disorders

About us
Epigenetics

Epigenetics is a regulatory system that controls gene expression without affecting the makeup of the genes themselves. Regulation of gene transcription and translation are key biological determinants for cellular differentiation and function, and transcriptional imbalances play a significant pathogenic role in a number of human diseases.

More info
Therapeutic programs

ORYZON is a clinical stage biopharmaceutical company that leverages epigenetics to discover and develop innovative personalized therapeutics for patients with cancers and CNS disorders. We are able to identify and validate biomarkers and therapeutic targets through our epigenetic platform and translate them into advanced and personalized therapies.

More info
Latest News
  • 5 May 2022

    ORYZON reports results and corporate update for quarter ended March 31, 2022

    • Read more about ORYZON reports results and corporate update for quarter ended March 31, 2022
  • 3 May 2022

    ORYZON starts preclinical collaboration on Kabuki syndrome with Kennedy Krieger Institute and Johns Hopkins University

    • Read more about ORYZON starts preclinical collaboration on Kabuki syndrome with Kennedy Krieger Institute and Johns Hopkins University
  • 29 April 2022

    ORYZON to give updates on corporate progress in May

    • Read more about ORYZON to give updates on corporate progress in May
All News
Upcoming events
  • 16-24 May 2022

    BioEquity Europe

    Milan

    MI

    Italy

    • More details about BioEquity Europe
  • 23-26 May 2022

    H.C. Wainwright Global Investment Conference

    Miami

    FL

    United States

    • More details about H.C. Wainwright Global Investment Conference
  • 24-26 May 2022

    Foro MedCap BME

    Madrid

    Spain

    • More details about Foro MedCap BME
All Events
  • Company
    • Overview
    • Strategy
    • Team
  • Epigenetics
    • Epigenetics
    • LSD1
  • Programs
    • Pipeline
    • Iadademstat
    • Vafidemstat
    • Collaborations
    • Publications
  • Patients
    • Clinical Trials
  • Investors
    • Share Information
    • Financial Information
    • Inside information
    • Other relevant information
    • Analyst Coverage
    • Corporate Governance
    • Corporate Social Responsibility
  • News & Events
    • Press releases
    • Events
  • Contact
    • Contact
    • Email Alerts
    • Join us
  • © Oryzon Genomics, S.A. - All Rights Reserved

    • Legal
    • Privacy Policy
    • Cookie Policy